Helliwell, Amber M, Stockwell, Peter A, Edgar, Christina D et al. · International journal of molecular sciences · 2022 · DOI
This study looked at how a person's DNA changes during ME/CFS relapses by examining two patients' genetic material multiple times over several months as they experienced a relapse and recovery. The researchers found that during relapses, the patients' DNA showed much larger changes in a process called methylation (a chemical marking system that controls which genes are active) compared to healthy people. These changes affected genes involved in metabolism, immune function, and inflammation—processes that are important in ME/CFS.
Understanding what happens at the molecular level during ME/CFS relapses could help identify early warning signs and develop strategies to prevent or reduce relapse severity. This study demonstrates that DNA methylation patterns may serve as biomarkers for disease activity, potentially enabling personalized monitoring and intervention in individual patients.
This study does not prove that methylation changes cause relapses—only that they occur together. The small sample size (two patients) limits generalizability, and the findings must be replicated in larger populations before clinical applications can be established. The study also does not explain what triggers these methylation changes in the first place.
About the PEM badge: “PEM required” means post-exertional malaise was an explicit required diagnostic criterion for participant inclusion in this study — not that PEM was studied, observed, or discussed. Studies using criteria that do not require PEM (e.g. Fukuda, Oxford) are tagged “PEM not required”. How the atlas works →
Contribute
Private, reviewed by a human. Not a public comment thread.